Bellerophon Therapeutics Inc. | Mutual Funds
Mutual Funds that own Bellerophon Therapeutics Inc.
Vanguard Total Stock Market Index Fund
686,231
1.19%
0
0%
07/31/2018
Fidelity Select Biotechnology Portfolio
487,970
0.84%
0
0.01%
07/31/2018
Vanguard Extended Market Index Fund
269,993
0.47%
3,300
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
109,948
0.19%
0
0%
07/31/2018
Fidelity Advisor Biotechnology Fund
91,526
0.16%
-68,175
0%
07/31/2018
iShares Micro Cap ETF
62,629
0.11%
0
0.01%
09/06/2018
Fidelity Nasdaq Composite Index
58,922
0.1%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
36,993
0.06%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
23,000
0.04%
23,000
0.01%
12/31/2017
Vanguard Institutional Total Stock Market Index Fund
20,401
0.04%
0
0%
07/31/2018
| Address |
184 Liberty Corner Road
Warren New Jersey 07059
United States
|
|
Employees
|
- |
| Website |
http://www.bellerophon.com |
| Updated |
07/08/2019 |
| Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. |
